Indeed, pulmonary fibrosis can be treated with Nintedanib, an inhibitor of the downstream signaling of VEGF, PDGF, and FGF, which interferes with angiogenesis, and Sorafenib, a multikinase inhibitor that blocks VEGF signaling, has been used to target angiogenesis in hepatocellular carcinoma [64,65,66]. Here, VEGFA is linked to pulmonary fibrosis.